Latest Strategic Reviews News

AVADA Group Limited reported a statutory net loss of $17.6 million for FY25, driven by impairments and challenging trading conditions, while completing a major business transformation aimed at future growth.

AVADA Group Limited reported a significant net loss of $17.6 million for FY25, driven by major impairments in New Zealand and New South Wales operations amid challenging market conditions. The company completed a strategic consolidation of its Australian businesses and appointed new senior management to steer operational transformation.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Aerometrex reported a slight dip in overall revenue for FY25 but achieved record growth in its MetroMap subscription business, driving a 19.8% rise in EBITDA. Strategic shifts and new leadership position the company for a leaner, more profitable future.

PEXA Group delivered a solid FY25 with 16% revenue growth and a 21% rise in EBITDA, while preparing for a UK platform launch backed by NatWest. Despite statutory losses from impairments, the company strengthened its balance sheet and outlined a confident FY26 outlook.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

FortifAI Limited reported a 15% decline in game revenue to $4.3 million for FY2025 but achieved a significant 72% reduction in net loss to $1.99 million, supported by operational cost cuts and a $3.6 million capital raise.

CI1 reported a sharp 57% revenue decline in FY25 but reduced its comprehensive loss by 64% through strategic disposals and capital returns. The company’s financial services operations in Australia and Singapore faced tough market conditions, prompting a portfolio reshaping.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Resimac Group reported a 13% rise in operating profit for FY25, driven by strong asset growth and a major auto finance acquisition, while declaring a total dividend of 19 cents per share.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.